TY - JOUR T1 - Concurrent Use of Bedaquiline and Delamanid for the Treatment of Fluoroquinolone-resistant Multidrug-resistant Tuberculosis: A Nationwide Cohort Study in South Korea JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.03026-2020 SP - 2003026 AU - Yong-Soo Kwon AU - Doosoo Jeon AU - Hyungseok Kang AU - Jae-Joon Yim AU - Tae Sun Shim Y1 - 2020/01/01 UR - http://erj.ersjournals.com/content/early/2020/10/15/13993003.03026-2020.abstract N2 - Multidrug-resistant tuberculosis (MDR-TB), a major global health concern, requires long-term treatment with multiple drugs, which can cause many side effects [1]. Therefore, an effective regimen with a minimum number of drugs is essential to control this disease. Bedaquiline (Bdq) and delamanid (Dlm) are new drugs that exhibit good efficacy and safety for MDR-TB treatment [1]. However, adding only one of the new drugs to a regimen may be insufficient to cure this disease when the infecting strain has a high level of drug resistance, such as fluoroquinolone-resistant MDR-TB or extensively drug-resistant TB (XDR-TB) [1–3]. Therefore, the concurrent use of Bdq and Dlm can effectively strengthen the treatment regimen if the best practices in “off-label” use are followed [4–10]. This study analysed the efficacy and safety of concurrent use of Bdq and Dlm in patients with MDR-TB and XDR-TB treated under a programmatic condition.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Yan reports grants from National Institutes of Health, during the conduct of the study;.Conflict of interest: Dr. Kwon has nothing to disclose.Conflict of interest: Dr. Jeon has nothing to disclose.Conflict of interest: Dr. Kang has nothing to disclose.Conflict of interest: Dr. Yim reports and I received donations of linezolid (Zyvox) from Pfizer Inc. and Delamanid (Deltyba) from Otsuka Pharmaceutical Co. for the clinical trials which I serve(d) as a principal investigator..Conflict of interest: Dr. SHIM has nothing to disclose. ER -